Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX – Get Free Report) COO Tina Marriott sold 6,000 shares of the company’s stock in a transaction on Thursday, October 24th. The stock was sold at an average price of $6.31, for a total transaction of $37,860.00. Following the completion of the transaction, the chief operating officer now directly owns 521,138 shares in the company, valued at $3,288,380.78. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website.
Tina Marriott also recently made the following trade(s):
- On Thursday, September 26th, Tina Marriott sold 6,000 shares of Recursion Pharmaceuticals stock. The shares were sold at an average price of $7.00, for a total value of $42,000.00.
- On Thursday, August 29th, Tina Marriott sold 6,000 shares of Recursion Pharmaceuticals stock. The shares were sold at an average price of $7.56, for a total value of $45,360.00.
Recursion Pharmaceuticals Trading Down 0.9 %
NASDAQ:RXRX opened at $6.68 on Thursday. The company’s 50 day moving average is $6.68 and its 200-day moving average is $7.66. The company has a quick ratio of 6.07, a current ratio of 6.07 and a debt-to-equity ratio of 0.04. Recursion Pharmaceuticals, Inc. has a 12 month low of $4.97 and a 12 month high of $15.74. The firm has a market cap of $1.88 billion, a price-to-earnings ratio of -4.12 and a beta of 0.80.
Hedge Funds Weigh In On Recursion Pharmaceuticals
Several large investors have recently made changes to their positions in the business. Vanguard Group Inc. increased its position in Recursion Pharmaceuticals by 1.0% in the 4th quarter. Vanguard Group Inc. now owns 15,665,210 shares of the company’s stock worth $154,459,000 after buying an additional 158,376 shares during the period. Oxinas Partners Wealth Management LLC bought a new position in Recursion Pharmaceuticals during the first quarter worth $122,000. Sumitomo Mitsui Trust Holdings Inc. raised its stake in Recursion Pharmaceuticals by 12.6% during the 1st quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 10,362,803 shares of the company’s stock valued at $103,317,000 after purchasing an additional 1,159,023 shares during the last quarter. Azzad Asset Management Inc. ADV bought a new stake in Recursion Pharmaceuticals in the 1st quarter valued at $161,000. Finally, Janney Montgomery Scott LLC acquired a new stake in Recursion Pharmaceuticals in the 1st quarter worth $310,000. Institutional investors and hedge funds own 89.06% of the company’s stock.
Wall Street Analyst Weigh In
A number of equities analysts recently commented on the company. Leerink Partners dropped their price objective on Recursion Pharmaceuticals from $9.00 to $8.00 and set a “market perform” rating on the stock in a report on Tuesday, September 3rd. KeyCorp dropped their price target on shares of Recursion Pharmaceuticals from $16.00 to $12.00 and set an “overweight” rating on the stock in a research note on Thursday, July 11th. Jefferies Financial Group reduced their price objective on shares of Recursion Pharmaceuticals from $8.00 to $6.00 and set a “hold” rating for the company in a research note on Tuesday, September 3rd. Finally, Needham & Company LLC lowered their target price on shares of Recursion Pharmaceuticals from $16.00 to $11.00 and set a “buy” rating on the stock in a research report on Wednesday, September 4th. Four analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. According to MarketBeat, the company has a consensus rating of “Hold” and an average price target of $9.40.
Check Out Our Latest Stock Report on RXRX
About Recursion Pharmaceuticals
Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.
Recommended Stories
- Five stocks we like better than Recursion Pharmaceuticals
- The Most Important Warren Buffett Stock for Investors: His Own
- Boeing: Why Analysts Think Now’s The Time To Be Brave
- 5 Top Rated Dividend Stocks to Consider
- Advanced Micro Devices is Building Momentum with AI: Buy the Dip
- 3 Small Caps With Big Return Potential
- Can Evolv Stock Recover From Its Massive Self-Inflicted Drop?
Receive News & Ratings for Recursion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Recursion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.